Skip to main content
. 2019 Jun 15;42(1):54–61. doi: 10.1016/j.htct.2019.01.013

Table 2.

Certainty assessment of the outcomes – application of the GRADE system.

Outcomes Certainty assessment
Certainty Importance
Trials Risk of bias Inconsistency Indirectness of evidence Imprecision Other considerations
The absence of complete disease remission CCG 1962 POG 8866 Seriousa Seriousb Not serious Not serious Highly suspicious publication bias
All potential confounders would suggest a spurious effect, and yet no effect was observeda
Inline graphic
LOW
CRITICAL
Number of postdiagnosis events CCG 1962 DFCI 87-01 DFCI 05-001
DFCI 01-91
Seriousd Not serious Not serious Not serious Highly suspicious publication bias
All potential confounders would suggest a spurious effect, and yet no effect was observedc, d
Inline graphic
MODERATE
CRITICAL
Overall mortality DFCI 87-01
DFCI 05-001
Serious Seriouse Not serious Not serious Highly suspicious publication bias
All potential confounders would suggest a spurious effect, and yet no effect was observedc
Inline graphic
LOW
CRITICAL
Hypersensitivity CCG 1962 POG 8866 DFCI 05-001 Serious a Not serious Not serious Seriousf Highly suspicious publication bias
All potential confounders would suggest a spurious effect, and yet no effect was observeda
Inline graphic
LOW
CRITICAL

CI: confidence interval; RR: relative risk.

Explanations:

a

The POG 8866 recruited patients previously treated with native L-Asparaginase and who were in a second bone marrow relapse and included hypersensitive patients, circumstances that may influence the response to treatment.

b

The analysis of the studies showed an I2 > 70% (high heterogeneity between the trials).

c

The protocol DFCI 87-01 used only one dose of PEG-Asparaginase; the remainder of the treatment was performed with native L-asparaginase.

d

The protocol DFCI 91-01 did not report the calculation used for the number of patients randomized in the trial.

e

The analysis of the studies showed an I2 = 56% (considerable heterogeneity between the trials).

f

The CI demonstrated in the analysis for the CCG 1962 ([0.25, 101.95]) and POG 8866 ([0.39, 6.47]) are high, bringing imprecision to the effect estimate.